← Leaderboards
Michael Jeffrey Vinikoor
University Of Maryland Baltimore
$8,208,556
Attributed
$10,295,923
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,999,809 · 10
By mechanism
P01$7,081,616 · 2
R01$3,962,448 · 2
R37$2,189,677 · 1
R34$1,904,868 · 3
K01$526,006 · 1
P30$335,194 · 1
Top collaborators
- Karen L Cropsey6 shared
- Georg Michael Lauer4 shared
- Cassidy W. Claassen3 shared
- Jeremy Calvin Kane3 shared
- Robert E Schwartz1 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Owen R White$64,733,266
- Andrew P Goldberg$12,955,492
- Jay Steven Magaziner$43,042,435
- John David Sorkin$3,343,455
- Ivana Gojo$2,095,689
Others in their field
Top investigators on “Viral”
- Lawrence Corey · Fred Hutchinson Cancer Center$466,994,927
- David Heimbrook · Leidos Biomedical Research, Inc.$366,090,791
- Daniel R Kuritzkes · Brigham And Women'S Hospital$267,074,199
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$252,763,614
- Judith S. Currier · University Of California Los Angeles$185,434,785
- Constance Ann Benson · University Of California, San Diego$165,517,633
Research focus
ViralAntiretroviral TherapyZambiaAdultMortalityUnited States National Institutes Of HealthCaringParticipantResponsePersonsAfrica South Of The SaharaTrainingFundingPrevalenceEnrollmentCohortEpidemicProgramsTranslatingFollow-UpClinicAlcohol ConsumptionAlcoholsAdherence
Grant awards (37)
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,028,772
P01 · FY2025 · AA
Spatial omics to understanding HBV control in people with HIV coinfection$806,208
R01 · FY2025 · AI
HBV-specific T cell immunity in HBV/HIV coinfection$588,450
R37 · FY2025 · AI · contact PI
Global Health Reciprocal Innovations SWG$258,068
P30 · FY2025 · AI · contact PI
CHARTZ$205,754
P01 · FY2025 · AA · contact PI
HBV-specific T cell immunity in HBV/HIV coinfection$136,858
R37 · FY2025 · AI · contact PI
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$86,160
P01 · FY2025 · AA
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,131,143
P01 · FY2024 · AA
HBV-specific T cell immunity in HBV/HIV coinfection$725,950
R37 · FY2024 · AI · contact PI
CHARTZ$324,415
P01 · FY2024 · AA · contact PI
Global Health Reciprocal Innovations SWG$77,126
P30 · FY2024 · AI · contact PI
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,143,049
P01 · FY2023 · AA
HBV-specific T cell immunity in HBV/HIV coinfection$738,419
R37 · FY2023 · AI · contact PI
Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection$575,680
R01 · FY2023 · AI · contact PI
CHARTZ$311,161
P01 · FY2023 · AA · contact PI
Re-engagement at Discharge (Re-Charge): Improving post-hospital outcomes for HIV-infected adults in Zambia$226,459
R34 · FY2023 · MH
Feasibility of an integrated intervention to reduce advanced HIV disease mortality among hospitalized adults in Zambia$126,002
R34 · FY2023 · MH · contact PI
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,137,273
P01 · FY2022 · AA
Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection$642,704
R01 · FY2022 · AI · contact PI
CHARTZ$299,367
P01 · FY2022 · AA · contact PI
Re-engagement at Discharge (Re-Charge): Improving post-hospital outcomes for HIV-infected adults in Zambia$159,798
R34 · FY2022 · MH
Zambia Alabama HIV Alcohol Comorbidities Program (ZAMBAMA)$1,177,489
P01 · FY2021 · AA
Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection$638,647
R01 · FY2021 · AI · contact PI
CHARTZ$237,033
P01 · FY2021 · AA · contact PI
Re-engagement at Discharge (Re-Charge): Improving post-hospital outcomes for HIV-infected adults in Zambia$207,707
R34 · FY2021 · MH
Feasibility of an integrated intervention to reduce advanced HIV disease mortality among hospitalized adults in Zambia$132,759
R34 · FY2021 · MH · contact PI
Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection$642,573
R01 · FY2020 · AI · contact PI
Feasibility of an integrated intervention to reduce advanced HIV disease mortality among hospitalized adults in Zambia$258,725
R34 · FY2020 · MH · contact PI
FEASIBILITY AND PRELIMINARY EFFECTIVENESS OF A TRANSDIAGNOSTIC COGNITIVE BEHAVIORAL THERAPY TREATMENT APPROACH FOR ALCOHOL MISUSE INTEGRATED WITHIN HIV CARE IN ZAMBIA$122,315
R34 · FY2020 · AA
Mechanisms of HBV Functional Cure During Tenofovir-based ART in HIV/HBV Coinfection$656,636
R01 · FY2019 · AI · contact PI
Feasibility and preliminary effectiveness of a transdiagnostic cognitive behavioral therapy treatment approach for alcohol misuse integrated within HIV care in Zambia$241,287
R34 · FY2019 · AA
Feasibility of an integrated intervention to reduce advanced HIV disease mortality among hospitalized adults in Zambia$208,532
R34 · FY2019 · MH · contact PI
Feasibility and preliminary effectiveness of a transdiagnostic cognitive behavioral therapy treatment approach for alcohol misuse integrated within HIV care in Zambia$221,284
R34 · FY2018 · AA
Impact of antiretrovial therapy on liver fibrosis in Zambian HIV/HBV patients$136,126
K01 · FY2017 · TW · contact PI
Impact of antiretrovial therapy on liver fibrosis in Zambian HIV/HBV patients$136,474
K01 · FY2016 · TW · contact PI
Impact of antiretrovial therapy on liver fibrosis in Zambian HIV/HBV patients$137,570
K01 · FY2015 · TW · contact PI
Impact of antiretroviral therapy on liver fibrosis in Zambian HIV/HBV patients$115,836
K01 · FY2014 · TW · contact PI